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Objective. To examine the association between metformin use and cancer stage at diagnosis among elderly men with preexisting
diabetes mellitus and incident prostate cancer. Methods. This study used a population-based observational cohort of elderly
men (≥66 years) with preexisting diabetes and incident prostate cancer between 2008 and 2009 (𝑁 = 2, 652). Cancer stage at
diagnosis (localized versus advanced) was based on the American Joint Cancer Committee classification. Metformin use and other
independent variables were measured during the one year before cancer diagnosis. Logistic regressions with inverse probability
treatment weights were used to control for the observed selection bias. Results. A significantly lower percentage of metformin
users were diagnosed with advanced prostate cancer as compared to nonusers (4.7% versus 6.7%, 𝑝 < 0.03). After adjusting for
the observed selection bias and other independent variables, metformin use was associated with a 32% reduction in the risk of
advanced prostate cancer (adjusted odds ratio, AOR: 0.68, 95% confidence interval, CI: 0.48, 0.97). Conclusions. This is the first
epidemiological study to support the role of metformin in reducing the risk of advanced prostate cancer. Randomized clinical trials
are needed to confirm the causal link between metformin use and prostate cancer diagnosis stage.
1. Introduction
Individuals with diabetes, specifically those with type 2
diabetesmellitus (T2DM) have a higher risk formany cancers
such as the breast, colon and rectum, endometrium, liver, and
pancreatic cancers as compared to those without diabetes [1]
due to biological mechanisms and shared risk factors [2–4].
In preclinical studies, T2DM has been found to be associated
with increased levels of plasma insulin, insulin resistance, and
hyperglycemia, which may have a direct effect on the growth
of tumors [5, 6] leading to the development of many types of
cancers [1].
In the case of prostate cancer, an inverse relationship
between diabetes and cancer risk has been observed [3].
However, among men who developed prostate cancer, dia-
betes was associatedwith an advanced stage of cancer diagno-
sis [7, 8].Three population-based studies in the United States
(US) reported that the presence of diabetes was associated
with an increased risk for advanced prostate cancermeasured
either by stage or tumor grade. In case-control studies and
cohort studies, men with diabetes were less likely to be
diagnosed with localized stage of prostate cancer. The risk
ratio (RR) was 0.70, 95% CI = 0.56–0.86 for case-control
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studies, and the RR was 0.72, 95% CI 0.67, 0.77 for cohort
studies [7]. Although the exact biological mechanisms for the
link between diabetes and prostate cancer are not known,
it is speculated that men with diabetes have low levels of
androgen, which may be associated with advanced stage of
cancer at diagnosis [7, 8].
The main modality of treatment for diabetes is pharma-
cotherapy with antidiabetes drugs such asmetformin, thiazo-
lidinediones, sulfonylureas, and insulin. All classes of antidi-
abetes drugs may indirectly affect the risk of prostate cancer
by controlling hyperglycemia. Of special interest is the use
of metformin for diabetes management because of its unique
actions on insulin resistance and hyperinsulinemia [9] as well
as its anticancer properties [10–12]. A systemic review found
thatmetformin use reduced the risk of prostate cancer among
men with diabetes [13] perhaps by regulating adenosine
monophosphate-activated protein kinase (AMPK) pathways
[10] andmammalian target of rapamycin (mTOR) [12]. Based
on preclinical evidence, one can speculate that metformin
may also reduce the risk of advanced prostate cancer among
menwith diabetes and incident prostate cancer [14].This rela-
tionship between metformin and advanced prostate cancer
diagnosis was explored by one population-based study from
Canada [15]. The study investigators used a cohort of 119,315
men with diabetes and measured cancer stage using tumor
grade. After adjusting for other risk factors, the investigators
concluded that metformin use was not associated with the
advanced form of cancer diagnosis [15]. The investigators
of the study did not control for severity of diabetes, which
may have affected the findings. Controlling for diabetes
severity is important because individuals with severe diabetes
have micro- and macrovascular complications and may have
adverse pathological profiles [16].Therefore, diabetes severity
may alter the relationship betweenmetformin use and cancer
stage at diagnosis. Furthermore, the study did not control
for the observed selection bias between metformin users
and nonusers; such bias may lead to misleading findings on
the association between metformin use and cancer stage at
diagnosis. Thus, there is a need for population-based studies
to examine the relationship between metformin use and
cancer stage at diagnosis that control for a comprehensive
set of risk factors and the observed selection bias between
metformin users and nonusers.
Therefore, the current study is conducted to investigate
the association between metformin use and cancer stage at
diagnosis among elderly fee-for-service Medicare beneficia-
ries with T2DM and incident prostate cancer.
2. Methods
2.1. Study Design. A cohort study design was adopted with
a baseline and an index date as depicted in Figure 1. The
index date was defined as the date of diagnosis of prostate
cancer.The baseline period consisted of 12 months before the
index date. Diabetes, metformin use, and other independent
variableswere identified during the baseline period.The types
of initial cancer treatment were identified during the follow-
up period.
Baseline period: 12 months 
Index date:
diagnosis date of prostate cancer (2008-2009)
2007–2009
Figure 1: Schematic presentation of study design to examine the
relationship between metformin use and cancer stage at diagnosis.
2.2. Data Source. Datawere derived from the SEER-Medicare
linked database. The SEER data comprised 18 population-
based cancer registries having precise and accurate infor-
mation on all newly diagnosed cancer cases since 1973. At
present, the data consisted of a total of 1,847,363 cases of
all cancers and 340,769 cases of prostate cancer among the
elderly population whose age was at least 65 at the time
of diagnosis of cancer presenting. With 98% ascertainment
of cases with the medical records and the highest level
of certification of data quality from the North American
Association of Central Cancer Registries, the SEER data
are considered to be the most comprehensive and high-
quality population-based data on cancer incidence and their
treatment and outcomes. The Patient Entitlement and Diag-
nosis Summary File (PEDSF) provides information on the
cancer diagnosis up to ten cancers, types of cancers, cancer
stage, individual’s demographic attributes, marital status,
and tumor characteristics at the time of cancer diagnosis.
The Medicare is the primary health insurer for 97% of the
US population aged 65 years and older [17]. A total of
93% of men aged 65 years and older in SEER have been
linked to Medicare population enrollment records [18]. The
Medicare part of the database is comprised of the Medicare
Provider Analysis and Review (MEDPAR) files, the carrier
claims (old name, physician/supplier (NCH)), outpatient
(OUTPT), and Part D Event (PDE). The MEDPAR and
outpatient file include Medicare Part A claims records from
any short term or long term hospital or skilled nursing facility
stay from each calendar year while the outpatient file had
Part B claims with outpatient visits. Each record represents
an episode of hospital stay and has up to 10 diagnoses
according to the International Coding of Diseases, 9th Edition-
CodeModification (ICD-9-CM) and 10 ICD-9-CM procedures
during each stay, on the day of admission, and on the day
of discharge. The carrier file represents billing records from
physicians and noninstitutional providers and has procedure
codes according tothe Health Care Procedure Classification
Code (HCPCS) and the Common Procedural Terminology,
4th Edition (CPT-4) and ICD-9-CM procedure codes with
service dates [19]. Medicare introduced optional/volunteer
Part D plans in 2006 that cover prescription drugs benefit
through enrollment in a Medicare advantage prescription
drug plan (MA-PD) or a stand-alone drug plan (PDP).
Almost half of the Medicare Parts A and B enrollee were
also enrolled in Part D plans [20]. We utilized the data of
the Medicare Part D Event (PDE) file in addition to PEDSF,
MEDPAR, OUTPT, and NCH for the years 2007 to 2010. We
examined prostate cancer cases diagnosed between 2008 and
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Men with prostate cancer identified
using SEER site recode: 54 and ICD-10-code: C61.9
between 2008 and 2009
N = 74,791
Men diagnosed with prostate cancer as a primary cancer
and alive at the time of diagnosis
N = 67,028
Elderly men diagnosed with prostate cancer as primary cancer and alive
at the time of diagnosis between 2008 and 2009
N = 45,618
Elderly men diagnosed with T2DM and incident prostate cancer at age of
66 years and older, with malignant tumor, alive at the time of diagnosis, and
diagnosed between 2008 and 2009 
N = 7,424
Elderly men diagnosed with prostate cancer as primary cancer at age of
66 years and above, with malignant tumor, alive at the time of diagnosis, and
diagnosed between 2008 and 2009
with 13-month continuous eligibility in Medicare Part A and Part B
and no HMO enrollment during the period of 1 year before diagnosis
N = 2,652
(i) No Parts A and B enrollment or HMO 
(ii) No history of diabetes (N = 19,404)
enrollment (N = 18,790)
Reason for exclusion: 
(i) Men diagnosed with prostate cancer at 
(ii) Men with multiple cancers
(N = 7,119)
the time of death or autopsy (N = 644)
Reasons for exclusion: 
Reasons for exclusion: 
(ii) Men diagnosed with prostate cancer 
(iii) Invalid death status (N = 1,870)
at age of 65 or below (N = 19,523)
(i) Men with carcinoma in situ (N = 17)
Reasons for exclusion:
(ii) Missing value for cancer stage at 
(i) No Parts D enrollment (N = 8,517)
diagnosis (N = 105)
Figure 2: Study cohort development flow diagram for study population of elderly Medicare beneficiaries diagnosed with prostate cancer and
diabetes.
2009 so that we could study their medication status in a year
prior to diagnosis of cancer.
2.3. Study Cohort. The study cohort comprised 45,618 men
with incident prostate cancer diagnosed between 2008 and
2009. We excluded 42,966 cases for the following reasons:
those diagnosed with prostate cancer during the autopsy;
those who had multiple cancers; those who had carcinoma
in situ; those aged 65 years and younger; those who died
during the study period; those enrolled in Medicare Health
Maintenance Organizations; those not continuously enrolled
in Medicare Parts A, B, and D during the study period, and
those missing cancer stage at diagnosis. The details on the
study cohort selection process are provided in Figure 2.
After all the exclusions, the final study cohort consisted
of 2,652 elderly men with type 2 diabetes mellitus (T2DM)
and incident prostate cancer. To note, every year nearly half
of enrolled Medicare beneficiaries in Parts A and B are
also enrolled in Medicare Part D since 2006. Therefore, our
study population with prostate cancer and T2DM reduced
to 7,424 enrolled in Medicare Parts A and B to 2,652 with
enrollment Part D. To reduce the selection bias, we compared
the characteristics of elderly men with T2DM and incident
prostate cancer enrolled in Medicare Parts A and B to those
4 Journal of Diabetes Research
Table 1: Characteristics of the study cohort elderly Medicare beneficiaries with diabetes and incident prostate cancer by metformin use
SEER-Medicare linked database, 2007–2010.
All
Overall Metformin users Non-metformin-user
Sig.N % N % N %
2,652 100 948 35.7 1,704 64.3
Predisposing characteristics
Age at diagnosis, in years ∗ ∗ ∗
66–74 1,579 59.5 609 64.2 970 56.9
75+ 1,073 40.5 339 35.8 734 43.1
Race/ethnicity ∗
Whites 1,914 72.2 680 71.7 1,234 72.4
African American 323 12.2 108 11.4 215 12.6
Hispanic/Latino 150 5.7 70 7.4 80 4.7
Others 265 10.0 90 9.5 175 10.3
Marital status
Unmarried 222 8.4 73 7.7 149 8.7
Married 1,550 58.4 581 61.3 969 56.9
Divorced/separated 393 14.8 136 14.3 257 15.1
Others 487 18.4 158 16.7 329 19.3
Enabling characteristics
Quartile of median census of 2000 income ∗
$7–$34,522 664 25.0 265 28.0 399 23.4
$34,523–46,224 664 25.0 243 25.6 421 24.7
$46,229–62,764 664 25.0 229 24.2 435 25.5
$62,767–200,008 660 24.9 211 22.3 449 26.3
Quartile of median census of 2000 education
0–8.52 666 25.1 222 23.4 444 26.1
8.53–15.16 655 24.7 229 24.2 426 25.0
15.17–26.09 664 25.0 248 26.2 416 24.4
26.1–100 667 25.2 249 26.3 418 24.5
PSA screening
Yes 2,415 91.1 872 92.0 1,543 90.6
No 237 8.9 76 8.0 161 9.4
Visit to a PCP
Yes 1,858 70.1 672 70.9 1,186 69.6
No 794 29.9 276 29.1 518 30.4
Statin use ∗ ∗ ∗
Yes 1,576 59.4 656 69.2 920 54.0
No 1,076 40.6 292 30.8 784 46.0
Insulin ∗ ∗ ∗
Yes 102 3.8 62 6.5 40 2.3
No 2,550 96.2 886 93.5 1,664 97.7
External environment characteristics
SEER-regions ∗∗
Northeast 487 18.4 146 15.4 341 20.0
South 570 21.5 223 23.5 347 20.4
North-central 351 13.2 112 11.8 239 14.0
West 1,244 46.9 467 49.3 777 45.6
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Table 1: Continued.
All
Overall Metformin users Non-metformin-user
Sig.N % N % N %
2,652 100 948 35.7 1,704 64.3
Need characteristics
DCSI quartile ∗∗
0 to 0 846 31.9 305 32.2 541 31.7
1 to 1 476 17.9 195 20.6 281 16.5
2 to 3 811 30.6 297 31.3 514 30.2
4 to 13 519 19.6 151 15.9 368 21.6
Notes: based on the data of 2,652 elderlymen aged 66 years and older diagnosedwith prostate cancer between 2008 and 2009 using a surveillance, epidemiology,
and end-results- (SEER-) Medicare linked Part D data. Significant group differences by metformin use are based on chi-square tests. % represented in the
column is row percentages.
DCSI: diabetes complication severity index; PCP: primary care physician; PSA: prostate specific antigen; Sig.: level of significance. ∗∗∗𝑝 < 0.001; ∗∗0.001 ≤
𝑝 < 0.01; ∗0.01 ≤ 𝑝 < 0.05.
enrolled in Parts A, B, andD as shown in theAppendix.These
two sets of population shared similar characteristics.
2.4. Key Dependent Variable
2.4.1. Cancer Stage at Diagnosis. The American Joint Com-
mittee on Cancer (AJCC) Tumor-Node-Metastases (TNM)
classification was used to identify the stage of prostate cancer
from the PEDSF file. Based on the AJCC-TNM systems, men
were classified as having localized cancer stage if they had
T1 or T2 clinical stage with no regional lymph node (NX-
N0) involvement and absence of any distant metastasis (M0)
[21]. Men were classified as having advanced cancer if they
were diagnosed with T3 or T4 clinical stage with or without
regional lymph node (N1) or distant metastasis (M1).
2.5. Key Independent Variable
2.5.1. Metformin Use. Metformin use was identified using the
Medicare Part D files. Metformin prescriptions were identi-
fied using the national drug codes (NDCs). Men with at least
one prescription for metformin during the baseline period
were considered as metformin users and men without any
prescriptions for metformin were considered as nonusers.
2.6. Other Independent Variables
2.6.1. Conceptual Framework. We utilized the Anderson
Healthcare Behavior and Utilizations Model (ABM) model
[22] to classify the potential independent factors associated
with advanced prostate cancer.
Predisposing Characteristics. Predisposing characteristics
consisted of age at diagnosis, race, and marital status. These
were identified from the PEDSF. Age at the time of diagnosis
was categorized into two groups (66 to 74 years, ≥75 years).
Race/ethnicity was categorized into four groups: White,
African American, Latino, and others. Marital status was
categorized into four groups: married, divorced/separated,
unmarried, and others.
Enabling Characteristics. Enabling characteristics were as
follows: education, income, prostate specific antigen test, and
visits to primary care physicians.Median income andmedian
education at the census tract of residence were derived
from the PEDSF. Income and education were measured by
quartiles. The receipt of PSA test was identified using the fol-
lowing HCPCS codes: 84152, 84153, 84154, and G0103 using
the Medicare carrier files during the baseline period. The
presence or absence of primary care visits during the baseline
was identified using the provider specialty codes [23].
Need Characteristics. The presence of T2DM was identified
using at least one inpatient visit or two or more physician
visits with a primary or a secondary diagnosis codes for
T2DM (ICD-9-CM codes: 250.x0 or 250.x2) during the
baseline period. The severity of diabetes, oral antidiabetic
medication use, insulin use, statins use, and corticosteroid
use were considered as need factors. The Diabetes Com-
plications Severity Index (DCSI) was calculated using the
modified algorithm by Chang et al. [24]. The DSCI is based
on seven categories: retinopathy, nephropathy, neuropathy,
cerebrovascular, cardiovascular, peripheral vascular disease,
and metabolic conditions. Based on the severity of particular
types of complications, a score of 1 or 2was assigned to each of
the seven categories, with a total DCSI score ranging from 0
to 13.The DCSI scores were grouped into quartiles. Details of
the ICD-9-CM codes and the scoring algorithm are provided
in the Appendix. The use of oral antidiabetic medications,
insulin, statins, and corticosteroids was identified using the
NDCs recorded in the Medicare Part D files during the
baseline period.
External Environment Characteristics. The SEER data has 18
registries/regions which were categorized into four regions:
(1) Northeast, with two registries of Connecticut and New
Jersey; (2) South, with five registries of Kentucky, Louisiana,
Atlanta, Rural Georgia, and Greater Georgia; (3) North-
central, with two registries of Detroit and Iowa; and (4)
West, with Hawaii, New Mexico, Seattle-Puget Sound, Utah,
San Francisco-Oakland, San Jose-Monterey, Los Angeles,
Greater California, Arizona, Alaska, and Cherokee Nation.
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Table 2: Adjusted odds ratios and 95% confidence intervals from logistic regressions onmetformin use among elderlyMedicare beneficiaries
with diabetes incident prostate cancer surveillance, epidemiology, and end-results- (SEER-) Medicare linked data, 2007–2010.
AOR 95% CI Sig.
Predisposing characteristics
Age at diagnosis
66–74 years 1.31 [1.10, 1.56] ∗∗
75 years or above Ref.
Race/ethnicity
Whites Ref.
African American 0.91 [0.69, 1.21]
Latino 1.62 [1.12, 2.34] ∗∗
Others 0.80 [0.59, 1.10]
Marital status
Married Ref.
Unmarried 0.81 [0.59, 1.11]
Divorced/separated 0.94 [0.74, 1.20]
Others 0.83 [0.66, 1.04]
Enabling characteristics
Quartile of median census of 2000 income
$7–$34,522 1.72 [1.20, 2.46] ∗∗
$34,523–46,224 1.34 [0.97, 1.84]
$46,229–62,764 1.18 [0.89, 1.56]
$62,767–200,008 Ref.
Quartile of median census of 2000 education
0–8.52 1.24 [0.87, 1.77]
8.53–15.16 1.21 [0.90, 1.62]
15.17–26.09 1.18 [0.92, 1.51]
26.1–100 Ref
Visit to a PCP
Yes 1.12 [0.92, 1.35]
No Ref.
Statin use
Yes 1.94 [1.63, 2.31] ∗ ∗ ∗
No Ref
Insulin
Yes 2.95 [1.94, 4.49] ∗ ∗ ∗
No Ref.
Need factors
DCSI quartile
0 to 1 Ref.
2 to 2 1.13 [0.89,1.44]
3 to 3 0.98 [0.79, 1.21]
4 to 13 0.65 [0.51, 0.84] ∗ ∗ ∗
External environment characteristics
SEER-regions
Northeast Ref.
South 1.40 [1.06, 1.85] ∗
North-central 1.07 [0.78, 1.47]
West 1.37 [1.08, 1.75] ∗
Notes: based on the data of 2,652 elderlymen aged 66 years and older diagnosedwith prostate cancer between 2008 and 2009 using a surveillance, epidemiology,
and end-results- (SEER-) Medicare linked Part D data. Significant group differences are based on log-likelihood test for metformin use.
DCSI: diabetes complication severity index; PCP: primary care physician; Ref.: reference group; Sig.: level of significance; ∗∗∗𝑝 < 0.001; ∗∗0.001 ≤ 𝑝 < 0.01;
∗
0.01 ≤ 𝑝 < 0.05.
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Table 3: (a) Number and IPTW-adjusted percentage of men with
localized versus advanced stage of prostate cancer by metformin
use among elderlyMedicare beneficiaries with diabetes and incident
prostate cancer surveillance, epidemiology, and end-results- (SEER-
)Medicare linked database, 2007–2010. (b) Unadjusted and adjusted
odds ratios and 95% confidence intervals from (IPTW) logistic
regressions for advanced stage at diagnosis of cancer.
(a)
Localized Advance Sig.
Overall N Weighted% N Weighted%
2,493 93.7 159 6.3
Metformin use ∗
Yes 902 95.3 46 4.7
No 1,591 93.3 113 6.7
(b)
Advanced stage at diagnosis IPTW
Unadjusted odds ratios and 95% confidence intervals
OR 95% CI Sig.
Metformin
Yes 0.69 [0.49, 0.95] ∗
No Ref.
Adjusted odds ratios and 95% confidence intervals
AOR 95% CI Sig.
Metformin
Yes 0.68 [0.48, 0.97] ∗
No Ref.
Notes: based on the data of 2,652 elderly men aged 66 years and older
diagnosed with prostate cancer between 2008 and 2009 using a surveillance,
epidemiology, and end-results- (SEER-)Medicare linked data.% is weighted
percentage for IPTW. Significant differences are based on the log-likelihood
test using a logistic regression with IPTW weights. Adjusted model con-
trolled for predisposing, enabling, need, and external environment related
factors.
IPTW: inverse probabilities treatment weights; PSA: prostate specific anti-
gen level; PCP: primary care physician visit; Sig.: level of significance; ∗∗∗𝑝 <
0.001; ∗∗0.001 ≤ 𝑝 < 0.01; ∗0.01 ≤ 𝑝 < 0.05.
The Area Healthcare Resource Use Files (AHRF) were linked
to identify the number of radiation oncology units, and
urology units at the county-level with cancer cases and
quartiles of total radiation oncology and urology units were
created for each case [25].
2.7. Statistical Analyses. Significant group differences in the
study population characteristics by metformin use were
examined with chi-square tests. A binary logistic regression
was used to determine the associations between predispos-
ing, enabling, need, and external environment characteristics
and metformin use. C-statistics and area under the curve
were used to assess the model fit. The logistic regression was
used to derive inverse probability treatment weights (IPTWs)
and these standardized IPTWs were used to control for the
observed selection bias in regressions on the cancer stage.
Significant unadjusted associations between metformin
use and cancer stage at diagnosis were examined with
chi-square tests. The IPTW-adjusted multivariable logistic
regressions were used to analyze the relationship between
metformin use and cancer stage at diagnosis. As the odds
ratios and relative risk are approximately similar for the
events with low prevalence, such as advanced prostate cancer
(≤10%) [26], these terms risk ratio or odds ratio of advanced
prostate cancer were used interchangeably. All statistical
analyses were carried out using Statistical Analysis System
(SAS) version 9.4 (SAS Institute Inc., Cary, NC).
3. Results
3.1. Description of the Study Cohort. The study cohort con-
sisted of 2,652 elderly men with preexisting T2DM and
incident prostate cancer between 2008 and 2009. Table 1
represents the characteristics of the study cohort. An over-
whelming majority of men were Whites (92.3); 59.7% were
diagnosed with prostate cancer between the ages of 66 and 74
years; 58.6% were married; and 46.2% resided in theWestern
region of the US. Nearly three-quarters (70.0%) of study
cohort had a primary care visit. An overwhelming majority
(91.1%) had PSA test during the baseline period.
3.2. Description of the Study Cohort byMetforminUse. Table 1
also summarizes the characteristics of the study cohort by
metformin use. Overall, 35.6% of the study cohort had at
least one prescription of metformin during the baseline
period. Significant differences in predisposing, enabling,
need, and external environment factors by metformin use
were observed.
Table 2 describes the adjusted odds ratios (AOR) and 95%
CI for the metformin use among elderly men with diabetes
and prostate cancer. Elderly men aged 66 to 74 years as
compared to those aged 75 years and older (AOR: 1.31, 95%
CI: 1.10, 1.56), Latinos as compared to Whites (AOR: 1.62,
95% CI: 1.12, 2.34), those who received insulin as compared
to no insulin (AOR: 2.95, 95% CI: 1.94, 4.49), and those who
received statins as compared to no statins (AOR: 1.94, 95%CI:
1.63, 2.31) were more likely to receive metformin. Whereas,
elderly men with a severe DCSI score (4 to 13) were more
likely to receive metformin as compared to those with zero
or one DCSCI score (AOR: 0.65, 95% CI: 0.51, 0.84).
3.3. Metformin and Cancer Stage at Diagnosis. Table 3
describes the relationship betweenmetformin use and cancer
stage at diagnosis among elderly men with prostate cancer
and diabetes. Overall, 93.7% of the study population was
diagnosedwith localized prostate cancer; 6.3%was diagnosed
with advanced prostate cancer. A significantly lower per-
centage of metformin users were diagnosed with advanced
prostate cancer as compared to nonusers (4.7% versus 6.7%,
𝑝 < 0.03).
Table 3 also reports unadjusted odds ratios (OR) and
adjusted ORs (AOR) from IPTW logistic regressions for the
advanced prostate cancer among elderly men with T2DM
and prostate cancer. In unadjusted logistic regression, we
observed the association between metformin and risk of
advanced prostate cancer at diagnosis (OR: 0.69, 95% CI:
0.49, 0.95). After adjusting for predisposing, enabling, need,
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Table 4: Codes and algorithms to identify diabetes complication severity index (DCSI) developed by Young et al. and modified by Chang et
al.
Complications ICD-9-CM code DCSI score
Retinopathy
Diabetic ophthalmologic disease 250.5x 1
Background retinopathy 362.01 1
Other retinopathies 362.1 1
Retinal edema 362.83 1
CSME 362.53 1
Other retinal disorders 362.81, 362.82 1
Proliferative retinopathy 362.02 2
Retinal detachment 361.xx 2
Blindness 369.xx.00–0.99 2
Vitreous hemorrhage 379.23 2
Nephropathy
Diabetic nephropathy 250.4 1
Acute glomerulonephritis 580 1
Nephrotic syndrome 581 1
Hypertension, nephrosis 581.81 1
Chronic glomerulonephritis 582 1
Nephritis/nephropathy 583 1
Chronic renal failure 585
Renal failure NOS 586
Renal insufficiency 593.9
Neuropathy
Diabetic nephropathy 356.9, 250.6 1
Amyotrophy 358.1 1
Cranial nerve palsy 951.0, 951.1, 951.3 1
Mononeuropathy 354.0–355.9 1
Charcot’s arthropathy 713.5 1
Polyneuropathy 357.2 1
Cerebrovascular
TIA 435 1
Stroke 431, 433, 434, 436 2
Cardiovascular
Atherosclerosis 440.xx 1
Other IHD 411 1
Angina pectoris 413 1
Other chronic IHD 414 1
Myocardial infarction 410 2
Ventricular fibrillation, arrest 427.1, 427.3 2
Atrial fibrillation, arrest 427.4, 427.5 2
Other ASCVD 429.2 1
Old myocardial infarction 412 2
Heart failure 428 2
Atherosclerosis, severe 440.23, 440.24 2
Aortic aneurysm/dissection 441 2
Peripheral vascular disease
Diabetic PVD 250.7 1
Other aneurysms, LE 442.3 1
PVD 443.81, 443.9 1
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Table 4: Continued.
Complications ICD-9-CM code DCSI score
Foot wound + complication 892.1 1
Claudication, intermittent 443.9 1
Embolism/thrombosis (LE) 444.22 2
Gangrene 785.4 2
Gas gangrene 0.4 2
Ulcer of lower limbs 707.1 2
Metabolic
Ketoacidosis 250.1 2
Hyperosmolar 250.2 2
Other comas 250.3 1
Note: the table is adapted from the previous algorithm defined by Young et al. and modified by Change et al. to identify the severity of diabetes using claims
database. Severity index was based on a scale ranging from 0 to 2 for each complication as follows: 0 = no abnormality, 1 = some abnormality, and 2 = severe
abnormality.
ASCVD, atherosclerotic cardiovascular disease; CSME, cystoid macular edema/degeneration; DCSI, diabetes complications severity index; IHD, ischemic
heart disease; ICD-9-CM, international classification of diseases, ninth revision, clinical modification; LE, lower extremity; NOS, not otherwise specified; PVD,
peripheral vascular disease; TIA, transient ischemic attack.
and external environment factors among elderly men with
prostate cancer and diabetes, metformin use was significantly
associated with a reduction in the risk of advanced prostate
cancer (AOR: 0.68, 95% CI: 0.48, 0.97).
4. Discussion
The current study is the first largest population-based study
to examine whether the risk of advanced prostate cancer
diagnosis is reduced with metformin use among elderly
men with preexisting T2DM and incident prostate cancer in
the US. Characteristics of metformin users were consistent
with literature. We observed that a higher percentage of
men living in the Western region of the united states were
prescribed metformin as compared to those living in other
regions. Census-track level income was also associated with
metformin use. These study findings are consistent with one
published study on geographical disparities in antidiabetes
medications. Regional disparities in metformin use can
reflect practice patterns in regions [26].
We found that the risk for advanced stage cancer diagno-
sis is reduced with metformin use among elderly men with
T2DM and incident prostate cancer after controlling for the
observed section bias betweenmetformin users and nonusers
and other independent variables.The current study addressed
the limitations of the single population-based examination of
metformin use and the cancer stage by incorporating a vali-
dated diabetes severity complications index and controlling
for the observed selection bias. The current study findings
are consistent with the preclinical evidence on the role of
metformin in prevention of advanced prostate cancer [10, 27].
Further, it should be noted that neither oral antidiabetic
medications (sulfonylurea and thiazolidinedione) nor insulin
use was associated with advanced prostate cancer (data
not shown in tabular format). Therefore, it is plausible that
metformin may act via insulin-independent pathways to
reduce the risk of advanced prostate cancer. If the findings
of the current study are confirmed by other population-
based studies, randomized clinical trials can be conducted to
establish the causal link between metformin use and risk of
advanced prostate cancer diagnosis.
It should be noted that the current study controlled
for the observed selection bias because metformin users
and nonusers were significantly different with respect to
their predisposing, enabling, need, and external environment
characteristics. Without adjustments for the observed selec-
tion bias, there was not a statistically significant difference
in the cancer stage between metformin users and nonusers.
Therefore, accounting for the observed selection bias is
important in establishing an association between metformin
use and the reduction in the risk of advanced prostate cancer
diagnosis.
The current study has a number of strengths. The large
cohort size and high-quality data on the clinical and patho-
logical features of cancer at the time of diagnosis enabled us
to examine not only the association between metformin use
and the cancer stage diagnosis but also the initial choice of
cancer treatment [18]. Furthermore, the inclusion of variable
on severity of diabetes using a validated method enabled
controlling and relating the effect of severity of disease on the
risk of advanced prostate cancer at diagnosis and receipt of
initial cancer treatment.
The current study has some limitations as well. The
prescription claims formetformin and other drugswere used.
Filling the prescriptions cannot be equated to the actual use
of these drugs. We made an attempt to overcome this issue
to some extent via measuring the one-year adherence to
medication, and a lower proportion of those with adherence
to metformin and nonadherent metformin had advanced
prostate cancer as compared to nonusers. Due to lack of
sufficient sample size, we did not present the results in tabular
format. However, the direction of our findings is consistent
with the previous studies suggesting no difference in the ever
metformin users and adherent metformin users on grade of
prostate cancer [15]. Secondly, we focused on elderly men
with prostate cancer because two-thirds of prostate cancers
cases are diagnosed among the elderly men aged 65 years and
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Table 5: Baseline characteristics of elderly men with prostate cancer with T2DM overall and enrolled in Part D program SEER-Medicare
linked database, 2008-2009.
All DM Part D (N = 2,652) DM overall (N = 7,424)
% %
Age at diagnosis, in years
66–74 59.5 59.4
75+ 40.5 40.6
Race/ethnicity
Whites 72.2 75.3
African American 12.2 14.5
Hispanic/Latino 5.7 3.0
Others 10.0 7.1
Marital status
Unmarried 8.4 6.6
Married 58.4 63.2
Divorced/separated 14.8 14.0
Others 18.4 16.2
Quartile of median census of 2000 income
$7–$34,522 25.0 24.9
$34,523–46,224 25.0 25.1
$46,229–62,764 25.0 25.0
$62,767–200,008 24.9 25.0
Quartile of median census of 2000 education
0–8.52 25.1 25.0
8.53–15.16 24.7 25.0
15.17–26.09 25.0 25.1
26.1–100 25.2 25.0
Visit to a PCP
Yes 70.1 65.0
No 29.9 35.0
PSA screening in past year
Yes 91.1 88.4
No 8.9 11.6
SEER-regions
Northeast 18.4 19.3
South 21.5 24.9
North-central 13.2 11.8
West 46.9 44.0
Quartile of radiation oncology
0 to 1 26.1 26.1
2 to 6 24.7 24.7
7 to 22 25.3 25.3
23 to 147 23.9 23.9
Quartile of urology centers
0 to 3 24.5 24.5
4 to 16 24.7 24.7
17 to 44 26.2 26.2
45 to 343 24.5 24.5
Year of diagnosis
2008 50.9 51.6
2009 49.1 48.4
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older [28]; however, the study population consisted of elderly
men with T2DM residing in SEER-regions and enrolled in
fee-for-services Medicare Parts A, B, and D plans; therefore,
one cannot generalize the study finding to younger men or
all Medicare beneficiaries with incident prostate cancer in the
US. Information on many important prognostic factors such
as body-mass index and smoking could not be adjusted; these
factors may be associated with an increased risk of advanced
prostate cancer diagnosis. Duration of metformin use could
not be adjusted due to data limitations. Future studies need
to examine whether a greater duration of metformin use is
associated with a decrease in the risk of advanced prostate
cancer at diagnosis. As the study population was restricted to
elderly men with T2DM, the current study findings cannot
be generalized to men without T2DM and incident prostate
cancer.
5. Conclusions
Metformin use was associated with a statistically significant
reduction in the risk advanced prostate cancer diagnosis
among elderly men with T2DM and incident prostate cancer.
The current study findings highlight the need for additional
studies in this area. Other population-based studies need to
be conducted to confirm the study findings. If confirmed,
randomized controlled trials can be carried out to examine
the causal link between metformin use and the risk of
advanced prostate cancer diagnosis.
Appendix
See Tables 4 and 5.
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